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Objective: The purpose of the trial was to examine the impact of inhaled human insulin (INH) 
on patient or physician willingness to adopt insulin after oral diabetes agent failure.
Research design and methods: The EXPERIENCE trial was a one-year randomized con-
trolled trial conducted at primary, secondary and tertiary care facilities in Europe and North 
America. The primary study endpoint was difference in glycated hemoglobin (A1c) between 
randomized groups at 26 weeks, and results from that phase have been reported previously. The 
present report concerns results from the second 26-week extension phase. We also consider the 
applicability of the design. The trial recruited 727 patients with type 2 diabetes mellitus who, 
prior to randomization, were using two or more oral diabetes agents and whose A1c was 8.0%. 
Patients were randomized to two treatment settings: Group 1 (usual care with the option of INH) 
or Group 2 (usual care only). Usual care included adjusting oral therapy (optimizing current 
regimen or adding/deleting agents) and/or initiating subcutaneous (SC) insulin.
Results: At baseline, insulin was initiated by more (odds ratio [OR] 6.0;95% conﬁ  dence 
interval [CI] 4.2 to 8.8; P  0.0001) patients in Group 1 (86.2%; 76.7% INH plus 9.5% SC) 
than in Group 2 (50.7%; SC insulin only). The largest reduction from baseline in A1c was in 
Group 1 (−2.0 ± 1.2%) at Week 12 and in Group 2 (−1.8 ± 1.3%) at Week 26 (P = 0.003). At 
52 weeks, 79.8% were on insulin in Group 1 (67.4% INH; 12.4% SC) vs 58.1% (SC only) in 
Group 2, and mean (SD) changes in A1c from baseline were –1.9% (1.2%) and –1.8% (1.3%) 
in Groups 1 and 2, respectively (P = 0.05). Hypoglycemic event rates per patient month were 
0.3 and 0.1 in Groups 1 and 2, respectively (P  0.0001).
Conclusion: The EXPERIENCE trial showed that novel delivery technology can accelerate 
the adoption of insulin although some attenuation of differences is observed over time. And 
further, that this was achieved in a population of patients who appeared more ready to move 
to insulin therapy than observed in standard clinical practice, and a group of physicians who 
appeared more ready to adopt INH than the majority of physicians.
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Introduction
The burden of diabetes is attributable to the chronic conditions and complications of 
the disease, and continues to rise as a socioeconomic burden.1
Furthermore there is considerable evidence that improved blood glucose control in 
line with current guidelines in patients with type 2 diabetes decreases diabetic complica-
tions when insulin or insulin secretagogues, eg, sulfonylurea therapy, are used.2,3 Despite 
proven beneﬁ  ts insulin is often delayed in nonsevere patients and is rarely used as an 
alternative treatment.4 On one hand, patients delay insulin because of the lack of obvi-
ous symptoms; on the other hand physicians fear reducing the quality of life of patients 
when treating with insulin.5 A recent study on the development of a new self-adminis-
tered questionnaire showed signiﬁ  cant fears and barriers to insulin injections patients Diabetes, Metabolic Syndrome and Obesity: Targets & Therapy 2009:2 2
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felt restricted because of self-surveillance and liberty loss, 
bothered by being seen while injecting insulin or skin marks 
at injection site, and stressed because of injection site pain.6 
It has also been shown that treatment satisfaction accounted 
for patient preference for a particular insulin delivery system.7 
Consequently, the need for more acceptable ways of insulin 
administration continues to motivate technical advances: 
injection devices that combine ultra-thin needles with dose 
administration convenience (multiple doses, dose accuracy, 
dose memory, less conspicuous pen-like appearance), 
development of long-acting insulin analogs for reduction of 
hypoglycemia and injection frequency, and, more recently, the 
search for alternate routes of administration such as pulmonary 
delivery. In a recent report for the National Health Service 
(NHS) in the UK, Horne suggested that taking medicine was 
a variable behavior that is inﬂ  uenced by patients’ beliefs 
about their illness and treatment, but also by environmental 
factors including interactions with healthcare providers and the 
context of societal-policies and practice.8 More speciﬁ  cally 
concerning diabetes, Capelleri emphasized that treatment 
convenience, ease of use and social comfort contributed to 
patients’ satisfaction with insulin delivery systems.9
Conventionally-designed trials where all subjects are ran-
domized to only one intervention per study arm are likely to 
fail the goal to estimate adequately the impact of preference 
and acceptance of new technologies on biologic outcome 
measures such as A1c. Thus, to incorporate the effects of phy-
sician and patient preference, we designed a trial where both 
were able to choose between treatment options regardless of 
randomization.10,11 The EXPERIENCE study presented in this 
paper was designed to establish whether patients’ acceptance 
of insulin translates into improved glycaemic control upon 
introduction of an inhaled insulin delivery system. The results 
from the initial 26-week period demonstrated12 that, at base-
line, insulin was initiated by more patients in Group where 
inhaled insulin was available, and that mean (SD) changes 
in A1c from baseline were greater in this group than in Group 
with standard care only (adjusted treatment difference 0.2%; 
P = 0.004). In the present paper we will discuss results from 
the second 26-week period as well as lessons learned from 
this novel study design concept.
Methods
This trial was a 52 week-long, open, randomized (1:1), parallel, 
multicenter study with a two-week run-in period. Stratiﬁ  cation 
by previous diabetes treatment (ie, either two oral hypoglycemic 
agents (OAs) or three or more OAs) was employed. The study 
period between weeks 0 and 26 assessed the primary efﬁ  cacy 
endpoint (A1c) whereas the study period from week 26 to week 52 
was considered an extended treatment period. There were two 
randomized treatment groups: Group 1 consisted of subjects 
who were given the option to choose inhaled insulin treatment 
while Group 2 subjects did not have the option of inhaled insulin. 
Irrespective of the availability of inhaled insulin, any subject 
could choose to remain on their current treatment or start any 
other marketed treatment (eg, subcutaneous [SC] insulin, OAs) 
in agreement with their study physician. Importantly, the initial 
treatment decisions could be re-visited and changed either at 
any time in the event of signiﬁ  cant adverse drug reactions, 
or every three months in the event diabetes control remained 
unsatisfactory in the opinion of the treating physician, or at 
26 weeks for any other reason, eg, incompatibility with life style. 
Thus, unlike most other trials, this study design incorporated 
drug choice and change as “real world” factors thus permitting 
optimization of treatments beyond dose.
Secondary outcomes included the uptake of insulin 
therapy, the number of subjects achieving specified 
glycaemic control, fasting glucose and lipid levels, Diabetes 
Treatment Satisfaction Questionnaire (DTSQ), and Euroqol 
(EQ-5D) generic health status measures.
For the purpose of this study, a hypoglycemic episode 
was deﬁ  ned as one of the following:
1.  Characteristic symptoms of hypoglycemia (both neuro-
logical and nonneurological) with no blood glucose check 
that promptly resolve with food intake, subcutaneous 
glucagon, or intravenous glucose.
2.  Characteristic symptoms of hypoglycemia together 
with blood glucose check showing values of 59 mg/dL 
(3.3 mmol/L) or less.
3.  Any blood glucose measurement 49 mg/dL (2.7 mmol/L) 
or less, with or without symptoms.
Every hypoglycemic event had to be characterized with 
respect to severity. In order to characterize the event as 
severe, all three of the following criteria had to be met:
1.  The patient was unable to treat him/herself, and
2.  The patient exhibited at least one of the following neu-
rological symptoms:
 1.  Memory  loss
 2.  Confusion
 3.  Uncontrollable  behavior
 4.  Irrational  behavior
 5.  Unusual  difﬁ  culty in awakening
 6.  Suspected  seizure
 7.  Seizure
  8.  Loss of consciousness, and
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•  blood glucose was measured to be 49 mg/dL (2.7 mmol/L) 
or less
or:
•  If the blood glucose was not measured, the clinical 
manifestations were reversed by oral carbohydrates, 
subcutaneous glucagon, or intravenous glucose.
Events that do not meet all three criteria for severe hypo-
glycemia were characterized as “mild to moderate.”
While all patients had to undergo pulmonary function test-
ing (forced expiratory volume in one second [FEV1], carbon 
monoxide diffusing capacity [DLco]) prior to randomization 
and at Week 52 (or end of study), only subjects who started 
INH were required to have additional tests at Week 12, or 
more often depending on test results at Week 12 or in case of 
respiratory symptoms. Insulin antibody titers were assessed 
at baseline, week 26, and week 52 in all subjects.
Statistical methods
We hypothesized that insulin would be the major precursor 
to achieving a clinically important beneﬁ  t in A1c in subjects 
recruited to the trial, and that the availability of INH would 
lead to a difference in at least the initial uptake of insulin 
between the groups. Consequently the power calculation was 
based upon the expected difference in A1c between the groups 
derived from anticipated differences in insulin use.
There were no studies in the literature to facilitate the 
estimation of the expected minimum difference between treat-
ment groups for this type of study design in which patients are 
randomized to one of two treatment groups and then choose 
from several available treatments. The only data available to 
estimate the minimum difference between treatment groups 
were from a questionnaire-based feasibility study13 in which 
patients were randomized to these two choice groups and 
asked to indicate on a questionnaire what treatment option 
they would be willing to choose. In order to estimate the 
expected reduction in A1c for each treatment group, estimates 
had ﬁ  rst to be obtained for the percentages of patients who 
will choose each of the potential treatment options within 
each group. In the feasibility study, patients in the INH group 
indicated 40% would choose inhaled insulin, 10% would 
choose SC insulin, 20% would modify their oral regimen, 
and 30% would make no change. In contrast, patients in 
the control group indicated 14% would choose SC insulin, 
36% would prefer a modiﬁ  cation of their oral treatment, 
while the remaining 50% would not change their treatment. 
These data provided new insight into patient preferences, 
but also had limitations as with any questionnaire study in 
which patients are indicating what they would hypothetically 
choose. The expected average reduction in A1c after one 
year of treatment for each of the possible choices had also 
to be estimated. Estimates for treatment-speciﬁ  c effects on 
the primary endpoint (reduction from baseline in A1c) were 
derived from review of the literature (INH: 1.5% to 1.9%; 
SC insulin: 1.5 to 1.9%; oral agents: 0 to 1.0). Using both 
the possible range of biologic responses as well as a range of 
possible preferences for a given treatment option, we arrived 
at a range of possible trial outcomes suggesting that the most 
likely outcome would be a difference of 0.47% in the primary 
endpoint A1c. The sample size for the trial was thus estimated 
to require a minimum of 324 subjects per study arm to detect 
a mean difference of at least 0.4% between groups in the 
primary endpoint A1c (α = 0.05, β = 0.1) assuming that the 
standard deviation would not exceed 1.4% and the number 
of subjects dropping out would be less than 20%.
Results
Population
Between April 15, 2004 and April 15, 2005, 1,137 subjects 
were screened. Of these, 727 met the eligibility criteria of the 
study, were randomized and received treatment. Patients were 
recruited in 109 centers (mean 6.8 patients per center; SD 5.6). 
Patient ﬂ  ow is described in Figure 1. Just under half of the 
randomized subjects were female (44%). Overall, subjects 
had a mean age of 58.7 years and a mean BMI of 31 kg/m2 
(Table 1). Seventy three percent of subjects were taking two 
oral antidiabetic therapies at baseline, the remainder three 
or more. There were no major imbalances between groups 
at baseline with respect to demographic criteria or labora-
tory parameters (Table 1). The mean baseline A1c (SD) was 
9.3% (1.2%) in Group 1 and 9.2% (1.1%) in Group 2. There 
were subjects who prematurely discontinued from the study 
up to 12 October 2006 (last subject visit): 44 (12%) subjects 
in Group 1, and 37 (10%) subjects in Group 2. Of those, 
18 subjects in each group withdrew because for nonstudy-
related reasons. Twelve subjects in Group 1 and 4 in Group 2 
discontinued for adverse events.
Preferences of patients
Initial treatment
Insulin was added to current diabetes therapy by 86% of 
patients in Group 1 at baseline (266 subjects [76.7%] INH 
and 33 subjects [9.5%] SC insulin alone), compared to 
184 subjects (50.7%) in Group 2 (odds ratio [OR] 6.0; 95% 
conﬁ  dence interval [CI] 34.2 to 8.8; P  0.0001) (Figure 3). 
In Group 1, of those who adopted INH at baseline, 6 subjects 
(1.7%) also added intermediate- or long-acting SC insulin. Diabetes, Metabolic Syndrome and Obesity: Targets & Therapy 2009:2 4
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A total of 48 subjects in Group 1 were treated with oral agents 
alone including 25 (7.2%) subjects who switched/added a 
new oral agent without insulin and 23 (6.6%) subjects who 
optimized their current treatment regimen. By contrast, 
59 subjects (16.3%) in Group 2 did not add any new oral or 
insulin regimen at baseline and only optimized their current 
oral agent regimens. Another 120 subjects (33.1%) added a 
new oral agent. The majority of subjects in Group 2 added 
a SC insulin regimen (184; 50.7%).
Subsequent treatment
Subjects were able to change treatments at Weeks 12 or 
34 where existing treatment proved ineffective, and at Week 26 
for any reason. As a result, the number of subjects who had 
progressed to insulin increased in Group 1 by Week 26 to 
273 (78.7%) using INH and 37 (10.7%) using SC insulin. 
However, as a results of treatment change decisions made at the 
Week 26 visit, the number of subjects remaining on INH fell 
to 250 (70%) the same week, and by Week 52 to 234 (67.4%) 
while the number of subjects using SC or OA increased to 
12.4% and 20.2%, respectively (Figure 2). Approximately half 
the subjects had an oral agent discontinued, most often a secre-
tagogues. In Group 2, the number of subjects using insulin (SC) 
increased to 58.1% by Week 52 while the number of subjects 
using only OA further declined, to 41.9% (Figure 2).
Among the subjects using SC insulin in both Groups 
at baseline, 89% of subjects used a pen device for insulin 
administration. None used an insulin pump. There was no 
difference in pen use between the groups. During the study, 
patients in Group 2 more frequently initiated human analogue 
long-acting insulin with 99 (27%) initiating insulin glargine 
and 40 (11%) initiating insulin detemir compared to Group 1 
where 41 (12%) introduced insulin glargine, and 17 (5%) 
insulin detemir. While more than 90% of patients used INH 
without a SC long- or intermediate-acting insulin initially, 
24% had initiated additional SC insulin, usually long-acting, 
insulin at study end. Of those subjects using SC insulin at 
study end, 29% in Group 1 and 36% in Group 2 were on 
multiple daily injections combining short- and long-acting 
insulin preparations. The majority of SC subjects, however, 
was treated with long-acting insulin and OA (67% in Group 1, 
59% in Group 2).
Oral agent users
In both study groups, metformin remained the most common 
agent with a slight increase comparing baseline and Week 52 
(Group 1: 92%/93%; Group 2: 92%/96%). The overall pre-
scription of secretagogues in both groups decreased although 
more dramatically in Group 1, which may be related to the 
greater use of insulin (Figure 3). In both groups the use of 
sulphonylurea compounds dropped when comparing baseline 
and Week 26 (Group 1: 79%/56%; Group 2: 81%/66%) as did 
glinide use (Group 1: 11.8%/5.1%; Group 2: 11.6%/11.6%). 
Similarly, the use of thiazolidinediones (TZDs) was lower in 
Group 1 at 26 weeks (36%/19%) than in Group 2 (35%/36%) 
compared to baseline. Prescription of alpha-glucosidase 
inhibitors decreased by at least half in both groups compared 
to baseline (Group 1: 9%/4%; Group 2: 8%/4%). Other anti-
diabetic agents were sparsely (5%) prescribed throughout 
the trial period.
1137 patients screened
357 assigned to Group 1 
(Standard therapies + EXU)
373 assigned to Group 2
(Standard therapies only) 
44 discontinued 37 discontinued
313 completed trial
347 included in primary
efficacy analysis          
357 included in safety
analysis
336 completed trial
363 included in primary
efficacy analysis          
373 included in safety
analysis
Figure 1 Patient disposition.Diabetes, Metabolic Syndrome and Obesity: Targets & Therapy 2009:2 5
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Patient-reported outcome data were collected at baseline, 
at Week 26 and end of study visit using the DTSQ (s, c) and 
EQ-5D questionnaires.14–17 More than 80% of subjects com-
pleted the follow-up questionnaires. There was no difference 
between groups at Week 26 or Week 52 in the total DTSQc 
score (Δ = 0.74, 0.52, respectively; P = 0.09, 0.21, respectively) 
or EQ-5D utility score (Δ = 0.027; P = 0.07 both times).
Efﬁ  cacy
In both groups, A1c was signiﬁ  cantly reduced compared with 
baseline. The largest reduction from baseline in A1c was 
established in Group 1 (–2.0% ± 1.2%) at Week 12 and in 
Group 2 (–1.8% ± 1.3%) at Week 26. In both groups, these 
levels of A1c reduction were maintained thereafter up to study 
end, albeit not always statistically signiﬁ  cant (Table 2). When 
assessing efﬁ  cacy based on a categorical variable, ie, percent 
of subjects achieving an A1c of less than 7%, the results were 
similarly in favor of Group 1 (Table 2).
In both groups, fasting plasma glucose was signiﬁ  cantly 
reduced but there was no difference (P = 0.20) between the 
groups despite the less frequent use of long- or intermedi-
ate acting insulin (29% vs 61%) used in Group 1: Group 1: 
57.2 ± 61.0 mg/dl (3.2 ± 3.4 mmol/l); Group 2: 57.0 ± 60.6 mg/dl 
(3.2 ± 3.4 mmol/l). Fasting blood lipid levels also decreased in 
both groups. Total cholesterol declined by 0.26 ± 0.84 mmol/L 
in Group 1 and 0.17 ± 0.90 mmol/L in Group 2. Similarly, 
triglyceride levels were reduced in both groups (Group 1: 
0.54 ± 1.46 mmol/L; Group 2: 0.51 ± 1.03 mmol/L).
Body weight increased in both groups from baseline 
(Group 1: +2.2 ± 4.8 kg; Group 2: +2.1 ± 4.9 kg). The 
adjusted weight difference between groups was 0.02 kg 
(P = 0.95) and appeared to be driven by insulin use in both 
groups (INH: + 2.6 ± 4.6 kg; SC insulin, Group 1 and 2 com-
bined: +2.7 ± 4.8 kg) whereas subjects remaining on oral agents 
had smaller or no weight changes (Group 1 and 2 combined: 
OA added: +1.0 ± 5.5 kg; OA unchanged : +0.2 ± 4.7 kg).
Table 1 Baseline patient demographics
Group 1: Standard therapies 
including INH N = 355
Group 2: Standard therapies 
N = 372
Mean age ± SD (range) [years] 58.7 ± 9.0 (32–78) 58.7 ± 9.2 (37–79)
Female (%) 153 (43.1%) 164 (44.6%)
Mean duration of diabetes (range) [years] 11.1 (1.3–45.1) 11.1 (1.1–44.3)
Mean A1c at screening ± SD (range) [%] 9.3 ± 1.2 (7.9–14.2) 9.2 ± 1.1 (7.3–16.3)
Mean BMI ± SD (range) [kg/m2] 30.9 ± 4.5 (21.5–42.4) 31.1 ± 4.8 (20.6–42.9)
Mean fasting plasma glucose ± SD (range) [mmol/l] 11.7 ± 2.9 (4.01–22.9) 11.1 ± 2.6 (5.3–20.0)
Mean triglycerides ± SD (range) [mmol/l] 2.4 ± 2.0 (0.5–23.1) 2.2 ± 1.3 (0.5–9.7)
Mean total cholesterol ± SD (range) [mmol/l] 5.1 ± 1.1 (2.6–9.6) 4.9 ± 1.0 (2.1–8.9)
Mean HDL ± SD (range) [mmol/l] 1.3 ± 0.3 (0.5–2.6) 1.3 ± 0.3 (0.4–2.7)
Mean LDL ± SD (range) [mmol/l] 2.8 ± 0.9 (0.8–6.6) 2.7 ± 0.8 (0.1–6.0)
Median systolic BP [mmHg] (IQR) 135 (125–144) 134.5 (125–145)
Median diastolic BP [mmHg] (IQR) 80 (73–84) 80 (72.1–85)
Median DTSQ (IQR) 27 (21–33) 27 (22–32)
Median EQ-5D 0.80 (0.73–1.00) 0.80 (0.73–1.00)
Pre-study oral agent combinations*
N = 347 N = 363
Two oral agent combination 253 (72.9%) 266 (73.3%)
SU + Met [%] 166 (47.8%) 176 (48.5%)
Met + TZD [%] 28 (8.1%) 26 (7.2%)
Met + Glinides [%] 24 (6.9%) 28 (7.7%)
SU + TZD [%] 21 (6.1%) 17 (4.7%)
Three oral agent combination 94 (27.1%) 97 (26.7%)
SU + Met + TZD [%] 56 (16.1%) 69 (19.0%)
SU + Met + α-glucosidase inhibitor 12 (3.5%) 11 (3.0%)
Abbreviations: BMI, body mass index; BP, blood pressure; DTSQ, Diabetes Treatment Satisfaction Questionnaire; EQ-5D, EuroQol Questionnaire; HDL, high-density lipoprotein; 
INH, inhaled human insulin; IQR, interquartile range; LDL, low-density lipoprotein; Met, metformin; SD, standard deviation; SU, sulfonylurea;   TZD, thiazolidinediones.
Note: *Other two and three oral agents were used but 3% of patient population.Diabetes, Metabolic Syndrome and Obesity: Targets & Therapy 2009:2 6
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Safety
Seventy nine percent of subjects in Group 1 and 70% of subjects 
in Group 2 reported at least one treatment-emergent adverse 
event. Amongst serious adverse events, 3 subjects in Group 
2 and 2 subjects in Group 1, respectively, were diagnosed 
with neoplasms (Table 3). In Group 1, four subjects using 
INH discontinued therapy for reduction in pulmonary func-
tion by more than 15% (2), dyspnea (1) and cough (1). Other 
frequently-reported adverse events that were more frequently 
reported in Group 1 compared to Group 2 included increased 
cough, pharyngitis and upper respiratory tract infection.
Hypoglycemia was reported in 176 subjects in Group 1 
(51%) and 132 subjects in Group 2 (36%). 1000/1007 (Group 1: 
99.3%) and 624/626 (Group 2: 99.7%) of hypoglycemic 
episodes were classiﬁ  ed as ‘mild-moderate’. Severe hypogly-
cemia occurred in 7 subjects in Group 1 and in two subjects 
in Group 2. Overall, hypoglycemia rates were markedly 
higher in Group 1 during the ﬁ  rst 4–8 weeks compared to 
Group 2. In both groups, rates declined over time and were 
of similar magnitude from Weeks 12 on until end of the trial: 
0.1–0.2 events/subject month.
In either group, there were no signiﬁ  cant differences in 
FEV1 (mean ± SD) from baseline (2.75 ± 0.72 L in both groups) 
to Week 52 (Group 1: 2.71 ± 0.74 L; Group 2: 2.73 ± 0.71 L), 
or mean DLco (mean ± SD) from baseline (Group 1: 23.9 ± 6.0 
Group 2: 23.7 ± 5.7 ml/min/mmHg) to Week 52 (23.4 ± 6.5, 
23.5 ± 6.1 ml/min/mmHg, respectively).
At 52 weeks, signiﬁ  cantly more (88%) subjects on INH 
had measurable (3% binding) insulin antibody titers than 
subjects on SC insulin (33%) or on oral agents (1%).
Discussion
In the EXPERIENCE trial, INH accelerated adoption of 
insulin and marked improvement in glycemic control at six 
months, but not at one year. The reduction of A1c in both 
groups may be due in part to the high average A1c at baseline 
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(the protocol required A1c to be at least 8.0% at screening). 
However, subjects continuing oral agents alone also improved 
their A1c by approx 1.5%.
Despite higher hypoglycemia rates, especially at the 
beginning of the trial, and the need to perform with increased 
frequency glucose self-monitoring and additional pulmonary 
consults, most subjects remained on inhaled insulin up to the 
end of the study even when additional SC long-acting insulin 
became necessary to control glycemia.
Consistent with prior clinical experience, other side 
effects were limited to irritation of the upper respiratory tract 
(increased cough, pharyngitis), and increased anti insulin 
antibody titers. Two subjects discontinued INH because of 
changes in lung function.
There was reduced prescription of oral agents (sulfonylurea 
[SU] and TZD drugs; Figure 3) and long-acting insulin 
preparations in Group 1 compared to Group 2. Control of 
fasting glucose remained good in INH subjects even without 
co-prescription of long-acting insulin despite the short-acting 
pharmacokinetic proﬁ  le of INH. This conﬁ  rms that the phar-
macodynamic action of INH may differ from short-acting 
SC insulin as already observed in previous preclinical and 
clinical studies18–20 and include a longer duration of action 
than anticipated based on pharmacokinetic data. The reasons 
remain elusive at this time and await elucidation by further 
studies.
Commensurate with improvement of glycemic control, 
lipid levels improved in both groups significantly from 
baseline, particularly in those subjects using insulin whether 
inhaled or injected. The modest difference in glycemic control 
established early on in the study narrowed towards the end, 
possibly because some patients in Group 1 returned to oral 
agent therapy while patients in Group 2 continued to adopt 
insulin albeit at a slow pace. The reasons for some subjects to 
return to oral agent after initially having chosen insulin (inhaled 
or SC) is not known. In Group 1, that number was higher (31 
subjects or 12% from INH, 6 subjects or 18%) from SC, alto-
gether 47 subjects or 16%) compared to Group 2 (16 subjects or 
9%) but this result may have also been inﬂ  uenced by the slower 
adoption of insulin in Group 2 which remained well below that 
of Group 1 at Week 52. The absence of “forced” compliance 
with treatment targets may have contributed to reduced insulin 
use late in the study when improvements in glycemic control 
brought about by insulin no longer outweighed the downsides 
as convincingly as at the beginning of the study.
The EXPERIENCE study showed that, in both study arms, 
subjects chose insulin at a high rate leading to a marked fall in 
A1c. This may be viewed as a surprising outcome but the nature 
of the study intervention may explain this unexpected result. To 
mimic as closely as possible “real life”, we used an open label 
study design which allowed both study subjects and physicians 
to express personal preferences by freely choosing among 
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available treatments. In conventional controlled trials, subjects 
may decline to consent because of their a priori preferences for 
one of the treatments, or their outcomes may be worse because 
of poor adherence or a negative placebo-like effect.21
Whether intermittent insulin therapy in certain patient 
groups may achieve acceptable long-term control of diabetes 
is certainly an intriguing aspect of this trial that may warrant 
further research. Previous studies were not encouraging but 
were of limited size and duration.22,23
Assessment of attitudes of health care professionals 
and patients towards new technologies is important to the 
extent that these attitudes may inﬂ  uence appropriate uptake. 
The purpose of the EXPERIENCE trial was to address the 
potential increased acceptability of making inhaled insulin 
available compared with conventional injectable insulins, 
aiming to incorporating patients and physician choice which 
is commonly “designed out” in conventional randomized 
trials. One potential limitation of a randomized trial design 
in this context is that subjects may not be representative 
of clinical practice but patients may self select to be those 
ready to make changes to their management in order to 
achieve improved glycaemic control. This appeared to 
be a feature of the EXPERIENCE trial where uptake of 
insulin was substantially higher in the control group than 
that observed in observational studies24 where median 
time from initiation of last oral therapy to insulin uptake 
was almost eight years in an unselected cohort of mostly 
poorly controlled subjects. Further the questionnaire-based 
feasibility study13 conducted only three years prior to the 
EXPERIENCE trial, in largely different study centers, and 
including some patients taking less than two oral agents, 
which was undertaken to help estimate sample size for 
Table 2 Primary and secondary efﬁ  cacy endpoints
Efﬁ  cacy variable Group 1: Standard therapies 
including INH; N = 355
Group 2: Standard therapies; 
N = 372
P value for difference 
between groups
Change from baseline in mean A1c from 
baseline ± SD [%] at
 4  weeks −1.1 ± 0.8 −0.9 ± 0.9 0.0008
 12  weeks −2.0 ± 1.1 −1.6 ± 1.2 0.0001
 26  weeks −2.0 ± 1.2 −1.8 ± 1.3 0.0030
 34  weeks −2.1 ± 1.2 −1.8 ± 1.2 0.0011
 42  weeks −2.0 ± 1.2 −1.8 ± 1.3 0.1523
 52  weeks −2.0 ± 1.2 −1.8 ± 1.3 0.0491
  52 weeks (LOCF) −1.9 ± 1.2 −1.8 ± 1.3 0.2251
Percent subjects with A1c less than 7% at
 4  weeks 9.1 4.0 0.0027
 12  weeks 40.2 29.6 0.0004
 26  weeks 47.5 41.5 0.0315
 34  weeks 48.5 38.9 0.0023
 42  weeks 42.2 38.7 0.1990
 52  weeks 44.7 40.4 0.1424
  52 weeks (LOCF) 41.8 39.4 0.2190
Change from baseline in fasting plasma 
glucose ± SD (mmol/l) at 52 weeks
−3.2 ± 3.4 −3.2 ± 3.4 0.2007
Change from baseline in mean 
triglycerides ± SD (mmol/l) at 52 weeks
−2.6 ± 2.8 −2.8 ± 2.9 0.5740
Change from baseline in mean total 
cholesterol ± SD (mmol/l) at 52 weeks
−4.7 ± 18.8 −3.3 ± 18.1 0.7006
Change from baseline in mean 
HDL ± SD (mmol/l) at 52 weeks
+0.5 ± 3.7 +1.0 ± 4.3 0.4190
Change from baseline in mean 
LDL ± SD (mmol/l] at 52 weeks
−0.8 ± 13.9 +0.7 ± 14.4 0.3203
Abbreviations: HDL, high-density lipoprotein; INH, inhaled human insulin; LDL, low-density lipoprotein; LOCF, last observation carried forward; SD, standard deviation.
Notes: LOCF included subjects that had discontinued before the 52 Week visit: 347 (Group 1) and 363 (Group 2) subjects vs 302 and 324 subjects, respectively, completing 
the study at 52 weeks.Diabetes, Metabolic Syndrome and Obesity: Targets & Therapy 2009:2 9
Assessing the impact of a new delivery method of insulin 
the present study indicated a much lower willingness to 
adopt insulin (including inhaled insulin). Nonetheless, the 
feasibility study helped to estimate the inﬂ  uence the propor-
tional impact of choice differences on glycemic outcomes. 
As a result, even the small differences seen in the present 
study were statistically signiﬁ  cant although their clinical 
relevance may be uncertain.
On average subjects experienced substantial beneﬁ  ts in 
improved glycaemic control regardless of their therapy, and 
despite the increased uptake of insulin in the INH group, 
there was considerable dilution of the effect as both groups 
represent a mix of different treatment modalities. Although 
most subjects remained on their initially-chosen “lead” 
treatment, eg, inhaled or SC insulin, many had concurrent 
treatment changed, be it to reduce hypoglycemia or improve 
overall efﬁ  cacy, just as commonly practiced outside clinical 
trials. Thus, in the absence of similarly-designed studies it is 
difﬁ  cult to estimate how relevant the observed differences 
are. Furthermore, the trial showed that freedom to select the 
most appropriate (based on the physician’s and subject’s 
opinion) treatment reduces differences between treatment 
modalities compared to data generated by conventionally-
designed head-to-head trials.
An obvious limitation of the EXPERIENCE trial is that 
it failed to corroborate the adoption of Exubera inhaled 
insulin in clinical practice.25 This points to a further potential 
limitation of the EXPERIENCE trial, in that physicians may 
have self selected to have become investigators based upon 
a raised willingness to use inhaled insulin, and in particular 
this delivery system which may have been less appealing 
to many of their colleagues, maybe as a result of size or 
complexity of the delivery system which can signiﬁ  cantly 
inﬂ  uence the selection of therapeutics.26,27 Self-selection of 
both physicians and patients for clinical studies challenges 
the external validity of trials using designs such as this, 
although it remains highly desirable to have estimates of 
treatment effect based upon randomized trials. Thus further 
steps may be required to translate estimates of the relative 
uptake of insulin therapy in randomized trials into their likely 
consequences in populations of clinicians and patients that 
better reﬂ  ect clinical practice.
In conclusion, the EXPERIENCE trial showed that novel 
delivery technology can accelerate the adoption of insulin 
although some attenuation of differences is observed over 
time. And further, that this was achieved in a population of 
patients who appeared more ready to move to insulin therapy 
than observed in standard clinical practice, and a group of 
physicians who appeared more ready to adopt INH than the 
majority of physicians.
Disclosure
This study was sponsored by Pﬁ  zer Inc.
Table 3 Adverse events and hypoglycemia in the EXPERIENCE trial
Adverse events
Group 1 Group 2
n % n % P value
Cardiovascular 35 8 53 14.2 0.07
Respiratory overall 144 40.3 96 25.7 0.001
Cough 51 14.3 18 4.8 0.001
Pharyngitis 47 13.2 36 9.7 0.05
URTI 34 9.5 26 7.0 0.21
Dyspnea 6 1.7 2 0.5 0.16
Lung cancer* 1 0.3 0 0 0.49
Other neoplasms** 2 0.6 3 0.7 0.72
Hypoglycemia
Number of subjects with 1 event 176 49.3 134 35.9 0.02
Number of subjects with severe 
hypoglycemia
7 2.0 2 0.5 0.10
Crude event rate per subject month 0.25 0.15 NA
Crude event rate per subject month 
between Week 26 and Week 52
0.15 0.13 NA
Abbreviation: URTI, upper respiratory tract infection.
Notes: *Subject with pre-trial smoking history; **Group 1: prostate, skin; Group 2:   T-cell lymphoma, pancreas, breast.Diabetes, Metabolic Syndrome and Obesity: Targets & Therapy 2009:2 10
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